In summary, our data provides strong support for the role of mda-7/IL-24 as a suppressor of Her2/Neu-induced breast cancer and should encourage development of a therapy based on continuous mda-7/IL-24 delivery into tumor cells, and based on a preponderance of data in the literature in combination with other therapeutic agents. This evidence concerns the gene ERBB2 and breast carcinoma.